最新ニュース AnaptysBio (NASDAQ:ANAB) 株価情報

AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

AnaptysBio Inc

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Overweight and lowers the price target from $75 to $66.

News

Price Target

Analyst Ratings

ANAB

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $66

HC Wainwright &amp; Co. analyst Emily Bodnar maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and lowers the price target from $55 to $52.

HC Wainwright & Co. Maintains Buy on AnaptysBio, Lowers Price Target to $52

AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.65) by 30.91 percent. This is a 19.15 percent increase over losses of $(1.41) per share from the same period last year. The company reported quarterly sales of $30.02 million which beat the analyst consensus estimate of $6.87 million by 336.74 percent. This is a 804.67 percent increase over sales of $3.32 million the same period last year.

Earnings

Earnings Beats

AnaptysBio Q3 EPS $(1.14) Beats $(1.65) Estimate, Sales $30.02M Beat $6.87M Estimate

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and maintains $55 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $55 Price Target

<h3>Gainers</h3>
<ul>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 106.1% to $4.18 during Wednesday's regular session. The market value of their outstanding shares is at $4.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 51.76% to $0.63. The company's market cap stands at $9.3 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock rose 35.29% to $1.34. The company's market cap stands at $58.8 million. </li>
<li>Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) stock rose 33.25% to $53.46. The company's market cap stands at $2.4 billion. The company's, Q3 earnings came out today. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 32.83% to $14.27. The company's market cap stands at $309.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares rose 31.66% to $5.17. The company's market cap stands at $55.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock decreased by 37.0% to $0.2 during Wednesday's regular session. The company's market cap stands at $2.0 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) stock declined by 25.56% to $22.93. The company's market cap stands at $692.4 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined by 20.46% to $6.75. The market value of their outstanding shares is at $411.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) shares decreased by 20.14% to $24.36. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares declined by 15.32% to $10.98. The market value of their outstanding shares is at $613.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares decreased by 15.06% to $18.89. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APDN

CALC

CRMD

CVRX

ENSC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OMCL

OPCH

SAGE

THAR

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

AnaptysBio shares are trading lower. UBS maintained a Hold rating on the stock.

UBS analyst Eliana Merle maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Neutral and raises the price target from $23 to $33.

UBS Maintains Neutral on AnaptysBio, Raises Price Target to $33

U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Wednesday.
Shares of O-I Glass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 adjusted EPS <a href="https://www.benzinga.com/quote/OI/analyst-ratings">guidance below estimates</a>.
O-I Glass reported quarterly losses of 4 cents per share which missed the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $1.700 which missed the analyst consensus estimate of $1.761 billion.
O-I Glass shares dipped 18.4% to $10.15 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares dipped 22.5% to $23.86 in pre-market trading.</li>
<li>Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) shares fell 18% to $82.40 in pre-market trading after the company reported issued weak guidance for the third quarter.</li>
<li>Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) dipped 15.7% to $311.00 in pre-market trading following weak quarterly earnings.</li>
<li>Criteo S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) shares fell 15.1% to $36.21 in pre-market trading following weak quarterly sales.</li>
<li>Thryv Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) fell 13.7% to $15.80 in pre-market trading after the company priced its upsized $80 million public offering of 5,715,000 common shares at $14/share.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) declined 10.7% to $806.57 in pre-market trading after the company reported worse-than-expected third-quarter earnings and sales.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares fell 8.6% to $152.00 after the company reported third-quarter financial results.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) fell 8.4% to $47.17 in pre-market trading after gaining around 9% on Tuesday.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41599928/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-for-october">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CRTO

QRVO

THRY

WING

O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 21.6% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock rose 18.32% to $4.65. The company's market cap stands at $49.9 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares increased by 18.27% to $3.3. The company's market cap stands at $16.5 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock increased by 15.52% to $34.0. The market value of their outstanding shares is at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 15.38% to $1.95. The market value of their outstanding shares is at $117.4 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) shares increased by 14.47% to $4.27. The company's market cap stands at $42.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock fell 41.7% to $0.18 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.9 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares fell 21.43% to $24.2. The company's market cap stands at $730.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) stock decreased by 19.85% to $1.05. The market value of their outstanding shares is at $56.7 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock fell 14.31% to $0.42. The market value of their outstanding shares is at $27.0 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares declined by 13.65% to $0.95. The company's market cap stands at $23.9 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) shares fell 11.92% to $9.46. The market value of their outstanding shares is at $205.3 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRC

GLYC

HOOK

MTNB

SPRO

Tempest Therapeutics, Inc. - Common Stock

TPST

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 21.4% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock increased by 18.92% to $35.0. The company's market cap stands at $1.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock increased by 18.32% to $4.65. The market value of their outstanding shares is at $49.9 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock moved upwards by 18.27% to $3.3. The company's market cap stands at $16.5 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 15.38% to $1.95. The company's market cap stands at $117.4 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) stock rose 14.47% to $4.27. The company's market cap stands at $42.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares fell 42.2% to $0.18 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares decreased by 21.43% to $24.2. The market value of their outstanding shares is at $730.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares fell 19.12% to $1.06. The market value of their outstanding shares is at $57.2 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock declined by 15.94% to $0.41. The company's market cap stands at $26.5 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) stock declined by 14.13% to $0.94. The company's market cap stands at $23.8 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock fell 11.92% to $9.46. The company's market cap stands at $205.3 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In the latest quarter, 6 analysts provided ratings for AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for AnaptysBio, revealing an average target of $57.83, a high estimate of $90.00, and a low estimate of $30.00. Marking an increase of 9.8%, the current average surpasses the previous average price target of $52.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1729544483_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of AnaptysBio by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>John Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AnaptysBio. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AnaptysBio's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AnaptysBio's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind AnaptysBio</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>AnaptysBio: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: AnaptysBio's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 217.08%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: AnaptysBio's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -425.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): AnaptysBio's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -161.85%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): AnaptysBio's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.2%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: AnaptysBio's debt-to-equity ratio is below the industry average at 1.72, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts

Guggenheim analyst Yatin Suneja maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and raises the price target from $75 to $90.

Guggenheim Maintains Buy on AnaptysBio, Raises Price Target to $90

<h3>Gainers</h3>
<ul>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock moved upwards by 24.3% to $4.3 during Monday's pre-market session. The market value of their outstanding shares is at $516.1 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock increased by 16.2% to $6.67. The company's market cap stands at $20.1 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares increased by 14.28% to $2.8. The market value of their outstanding shares is at $3.2 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares increased by 13.81% to $10.3. The market value of their outstanding shares is at $11.0 million. As per the news, the Q2 earnings report came out today. </li>
<li>BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) stock increased by 13.01% to $9.12. The company's market cap stands at $152.1 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares rose 9.82% to $35.0. The market value of their outstanding shares is at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares fell 20.8% to $0.23 during Monday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares declined by 11.66% to $4.55. The company's market cap stands at $284.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 11.28% to $0.55. The company's market cap stands at $2.4 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 10.93% to $1.06. The market value of their outstanding shares is at $38.5 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 10.13% to $0.57. The company's market cap stands at $7.6 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares decreased by 7.5% to $0.66. The market value of their outstanding shares is at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

BNOX

BWAY

CRVS

ESLA

PRME

PTIX

TRAW

VERO

12 Health Care Stocks Moving In Monday's Pre-Market Session

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $54.43, accompanied by a high estimate of $75.00 and a low estimate of $30.00. Surpassing the previous average price target of $45.00, the current average has increased by 20.96%.
<img src="https://www.benzinga.com/files/images/story/2024/1727359275_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive AnaptysBio is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>John Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AnaptysBio. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for AnaptysBio's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AnaptysBio's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know AnaptysBio Better</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>Unraveling the Financial Story of AnaptysBio</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: AnaptysBio's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 217.08%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AnaptysBio's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -425.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -161.85%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): AnaptysBio's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -11.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.72.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About AnaptysBio Stock

Wedbush analyst David Nierengarten reiterates AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Outperform and maintains $42 price target.

Wedbush Reiterates Outperform on AnaptysBio, Maintains $42 Price Target

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out<a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#8217;s insider transaction</a>s platform.
<h3 class="wp-block-heading">AnaptysBio</h3>
<ul>
<li>The Trade: AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) 10% owner Ecor1 Capital, LLC <a href="https://www.benzinga.com/quote/ANAB/analyst-ratings">acquired a total of 273,972 shares </a> at an average price of $36.50. To acquire these shares, it cost around $10 million.</li>
<li>What's Happening: On Aug. 14, the company announced a public offering of 2,750,498 shares of common stock at $36.50 per share.</li>
<li>What AnaptysBio Does: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology.</li>
</ul>
<h3 class="wp-block-heading">Forum Energy Technologies</h3>
<ul>
<li>The Trade: Forum Energy Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FET#NYSE">FET</a>) President and CEO Neal Lux acquired a total of 13,500 shares at an average price of $15.82. To acquire these shares, it cost around $213,570.</li>
<li>What's Happening: On Aug. 1, Forum Energy Technologies posted downbeat quarterly results.</li>
<li>What Forum Energy Technologies Does: Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries.</li>
</ul>
<h3 class="wp-block-heading">Yum China</h3>
<ul>
<li>The Trade: Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) General Manager, KFC Warton Wang <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 3,700 shares</a> at an average price of $34.67. To acquire these shares, it cost around $128,267.</li>
<li>What's Happening: On Aug 5, Yum China reported a second-quarter earnings beat and announced a CFO transition.</li>
<li>What Yum China Does: With almost 13,000 units and USD 10 billion in systemwide sales in 2022, Yum China is the largest restaurant chain in China.</li>
</ul>
Read More<a href="https://www.benzinga.com/markets/24/08/40420521/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">: </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40420521/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></li>
</ul>

Long Ideas

Insider Trades

YUMC

Insiders Buying Yum China And 2 Other Stocks

Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Hold and raises the price target from $20 to $30.

Truist Securities Maintains Hold on AnaptysBio, Raises Price Target to $30

U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Wednesday.
Shares of UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) rose during Wednesday's session following strong s<a href="https://www.benzinga.com/news/earnings/24/08/40360422/ubs-q2-earnings-beats-wealth-management-shines-cost-savings-accelerate-more">econd-quarter earnings.</a>
UBS Group reported second-quarter FY24 sales of $11.9 billion, up 25% Y/Y, beating the consensus of $11.3 billion.
Underlying operating profit before tax reached $2.06 billion, significantly higher than $891 million a year ago. EPS of 34 cents beat the consensus of 12 cents.
UBS shares gained 5.6% to $30.89 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) shares jumped 29% to $13.40 after the company announced a partnership with Shake Shack to deliver products using autonomous delivery robots through Uber Eats.</li>
<li>Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) surged 21.9% to $41.43 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) gained 18.8% to $39.62 after the company announced a public offering of 2,750,498 shares of common stock at $36.50 per share.</li>
<li>Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) gained 17.1% to $22.33 after the company announced a new CEO and reported strong preliminary second-quarter financial results.</li>
<li>Nkarta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) surged 13.7% to $5.65 following upbeat quarterly earnings.</li>
<li>Marex Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) gained 13% to $23.56 after the company reported better-than-expected second-quarter financial results.</li>
<li>Smith Douglas Homes Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NASDAQ">SDHC</a>) jumped 12.2% to $36.54 after the company reported better-than-expected second-quarter revenue results..</li>
<li>Intapp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>) gained 12.1% to $38.11 after the company reported strong fourth-quarter earnings and issued guidance.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) gained 11.3% to $2.2250 following quarterly results.</li>
<li>Performance Food Group Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) climbed 9.7% to $73.58 after the company reported better-than-expected fourth-quarter adjusted EPS results.</li>
<li>XP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) gained 8.7% to $20.05 following second-quarter results.</li>
<li>Prelude Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) gained 8.6% to $6.73.</li>
<li>Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) gained 8% to $206.76 after the company reported a year-over-year increase in second-quarter financial results..</li>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) gained 7.9% to $80.39 following a report suggesting Mars is expected to pay $83.50 per share for the company.</li>
<li>Qifu Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) climbed 7.5% to $22.69 following second-quarter results.</li>
<li>LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) gained 7.1% to $213.53.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/news/24/08/40362640/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-with-over-3-dividend-yields"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40362640/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 3% Divi</a><a href="https://www.benzinga.com/news/24/08/40362640/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-with-over-3-dividend-yields">dend Yields</a></li>
</ul>

Intraday Update

CLOV

FLUT

INTA

LPLA

MRCY

NKTX

PFGC

PRLD

QFIN

SDHC

SERV

VSCO

UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday

The July Consumer Price Inflation report made another step toward the Federal Reserve&#8217;s 2% target, though less pronounced than June&#8217;s, sustaining optimism for <a href="https://www.benzinga.com/topic/inflation">imminent interest rate cuts.</a>
Last month, a basket of goods and services purchased by U.S. consumers rose by 2.9% year-over-year, slightly below the previous and expected 3%, marking the fourth consecutive decline in annual inflation and the <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40365730/july-inflation-rate-falls-more-than-expected-supports-hopes-for-large-fed-rate-cu">lowest rate since March 2021.</a>
The annual core inflation rate also eased as anticipated, from 3.3% to 3.2%, the lowest since April 2021. 
However, the July report was marred by an increase in the shelter component, which, due to its significant weight in the basket, accounted for about 90% of the headline inflation rise.
The decline in annual inflation rates wasn&#8217;t sufficient to bolster expectations for a 50-basis-point rate cut in September. 
Market-implied probabilities for such a substantial cut dropped from 50% to 43% following the report, while the likelihood of a smaller 25-basis-point cut increased to 57%.
<h3 class="wp-block-heading">Market Reactions: Stocks Rise, Yields Steady, But Dollar Strengthens Against Yen</h3>
The July inflation data sparked a positive reaction in stocks, especially in the tech sector, with small caps outperforming their larger-cap counterparts. Treasury yields remained largely stable, while the U.S. dollar gained ground against the low-yielding Japanese yen.
Here are the premarket price reactions of the following exchange-traded funds (ETFs) to the inflation data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.2% at 09:10 a.m. in New York. Major premarket gainers were Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) and Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 7.2% and 5.5% respectively. </li>
<li>The tech-heavy Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.3%. Top gainers were Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) and Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) up 3.1% and 3%, respectively. </li>
<li>Semiconductors were the strongest-performing industry, with the VanEck Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>) up 0.9%. Micron Technology Inc. and ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) led gains, with the latter up 2.1%. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 0.5%, with Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) and AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) making the larger gains in the premarket, up 16% and 13%, respectively. </li>
<li>The Invesco CurrencyShares Japanese Yen Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXY#NYSE">FXY</a>) fell 0.2%.</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/08/40355203/stocks-now-dismiss-recession-fears-but-bond-markets-tell-investors-to-stay-on-alert">Stocks Now Dismiss Recession Fears, But Bond Markets Tell Investors To Stay On Alert</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Small Cap

Economics

Federal Reserve

Tech

ETFs

ASML

S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday

From time to time, the company may offer up to $500M aggregate dollar amount of shares of its common stock or preferred stock, debt securities, war...

AnaptysBio files $500M mixed securities shelf

AnaptysBio ( ($ANAB) ) has released its Q3 earnings. Here is a breakdown of the information AnaptysBio presented to its investors. AnaptysBio, Inc....

AnaptysBio Reports Q3 2024 Financial Results and Updates

H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on ANAB stock, giving a Buy rating on November 4. Emily Bodnar's rating is...

Promising Pipeline Developments Position AnaptysBio as a Buy: Focus on ANB032 and Rosnilimab

H.C. Wainwright lowered the firm's price target on AnaptysBio (ANAB) to $52 from $55 and keeps a Buy rating on the shares following the Q3 report. ...

AnaptysBio price target lowered to $52 from $55 at H.C. Wainwright

Wells Fargo analyst Derek Archila maintained a Buy rating on AnaptysBio (ANAB – Research Report) yesterday and set a price target of $56.00. Derek ...

Buy Rating for AnaptysBio Driven by ANB032 Potential and Diversified Pipeline

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on AnaptysBio (ANAB – Research Report), with a price tar...

Stifel Nicolaus Keeps Their Buy Rating on AnaptysBio (ANAB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Autolus Therapeutics (AUTL – Research Report), Molina Healthcare ...

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Molina Healthcare (MOH) and AnaptysBio (ANAB)

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on AnaptysBio (ANAB – Research Report). The company's shares closed ...

TD Cowen Reaffirms Their Buy Rating on AnaptysBio (ANAB)

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on AnaptysBio (ANAB – Research Report). The company's shares cl...

Comments

AnaptysBio

ニュース

最新ニュース AnaptysBio (NASDAQ:ANAB) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル